The Committee on Medical Affairs proposes the following amendment (SR-221.CEM0001S):

Amend the bill, as and if amended, SECTION 1, by striking Section 44-53-2020(A)(2)(c), (d), (e), and (f) and inserting:

   (c) contains a level of 7-hydroxymitragynine in the alkaloid fraction which is greater than two percent of the alkaloid composition of the product;
   (d)(c) contains a fully synthetic alkaloid including, but not limited to, fully synthetic mitragynine, fully synthetic 7-hydroxymitragynine, or any other fully synthetically derived compound of the plant mitragyna speciosa;
   (e)(d) contains levels of residual solvents higher than the standards set forth in Chapter 467 of the U.S. Pharmacopeia-National Formulary (USP-NF); or
   (f)(e) does not meet the labelling requirements established pursuant to Section 44-53-2030 and a regulation promulgated to implement the provisions of that section.

Amend the bill further, SECTION 1, by striking Section 44-53-2040 and inserting:

 Section 44-53-2040. A retailer found to be in violation of Section 44-53-2020 or 44-43-2030, or a regulation promulgated pursuant to the provisions of this article, is subject to a civil penalty of not more than five hundred one thousand dollars for a first offense and a civil penalty of not more than one two thousand dollars for a second or subsequent offense.

Renumber sections to conform.

Amend title to conform.